Company intelligence / Profile preview

dMed Global

New York City, New York, United States

Ownership: Private
Employees: ~1600
Development stage: Other

Overview

dMed Global is a full-service clinical contract research organization (CRO) with a strong geographic presence in China and the US, providing end-to-end clinical trial and regulatory services to biotech, pharma, and device companies globally. dMed merged with Clinipace in April 2021, resulting in a combined company with over 1,600 employees across 22 countries, and was renamed Caidya in 2022. The company specializes in oncology, nephrology, rare diseases, gastroenterology, and women’s health, with broad clinical experience and regulatory expertise[3][1][2].

Industry: Contract Research Organization

Beyond the preview

Go deeper on dMed Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dMed Global.

Explore the full profile